Abstract
Hybridon is developing immunomodulatory oligonucleotides. including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. HYB-2055 is currently undergoing phase II clinical trials. The immunomodulatory oligonucleotides are also being investigated for the potential treatment of infectious diseases and immune disorders.
MeSH terms
-
Animals
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Communicable Diseases / drug therapy
-
Humans
-
Immune System Diseases / drug therapy
-
Immunologic Factors / therapeutic use*
-
Injections
-
Mice
-
Neoplasms / drug therapy*
-
Oligonucleotides / adverse effects
-
Oligonucleotides / therapeutic use*
Substances
-
HYB-2055
-
Immunologic Factors
-
Oligonucleotides